Oruka Therapeutics (ORKA) grants director 9,136 stock options

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock. The options have an exercise price of $55.23 per share and expire on June 1, 2036. According to the footnote, the award vests in equal monthly installments over 12 months starting June 2, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kulkarni Samarth

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	9,136	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 9,136 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 9,136 options Exercise price: $55.23 per share Post-transaction derivative holdings: 9,136 options +3 more

6 metrics

Options granted 9,136 options Grant of stock options to director on June 2, 2026

Exercise price $55.23 per share Strike price for underlying common stock

Post-transaction derivative holdings 9,136 options Total options held after reported grant

Grant price $0.00 per option Reported transaction price per option on Form 4

Expiration date June 1, 2036 Option award expiration

Vesting schedule 1/12 monthly from June 2, 2026 Footnote describing vesting of underlying shares

Key Terms

Stock Option (right to buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 55.2300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vesting financial

"The option vests as to 1/12 of the underlying shares monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$55.23	06/02/2026		A		9,136		(1)	06/01/2036	Common Stock	9,136	$0	9,136	D

Explanation of Responses:

1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Samarth Kulkarni	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Oruka Therapeutics (ORKA) insider Samarth Kulkarni report on this Form 4?

Samarth Kulkarni reported receiving a grant of stock options for 9,136 shares of Oruka Therapeutics common stock. The options were acquired at a grant price of $0.00 per option, reflecting a typical award structure rather than an open-market purchase.

What is the exercise price of the new Oruka Therapeutics (ORKA) stock options?

The granted options have an exercise price of $55.23 per share for the underlying Oruka Therapeutics common stock. This means Kulkarni can buy shares at $55.23 once the options vest and before they expire, subject to the terms of the award.

How many Oruka Therapeutics (ORKA) options does Samarth Kulkarni hold after this transaction?

After this transaction, Kulkarni holds 9,136 stock options as reported in the Form 4. This figure reflects the total derivative securities following the grant and corresponds to options on 9,136 shares of Oruka Therapeutics common stock.

When do the new Oruka Therapeutics (ORKA) stock options granted to Kulkarni vest?

The option award vests as to 1/12 of the underlying shares monthly starting June 2, 2026. This creates a one-year vesting period during which a portion of the 9,136 options becomes exercisable each month until fully vested.

What is the expiration date of Samarth Kulkarni’s Oruka Therapeutics (ORKA) option grant?

The reported stock options expire on June 1, 2036, if not exercised earlier. After that expiration date, any unexercised portion of the 9,136-share option award will lapse and can no longer be used to acquire Oruka Therapeutics common stock.

Was this Oruka Therapeutics (ORKA) Form 4 transaction an open-market buy or a grant?

The Form 4 describes the transaction as a grant or award acquisition of derivative securities, not an open-market purchase. The transaction code is “A” and the price per option is $0.00, consistent with an option grant from the company.